维奈克拉联合低剂量阿糖胞苷治疗不适合强化化疗的新诊断AML:3期随机安慰剂对照试验
该国际3期随机双盲安慰剂对照试验纳入211例不适合强化化疗的新诊断AML成人患者,按2:1随机接受维奈克拉联合LDAC或安慰剂联合LDAC。中位OS分别为7.2个月和4.1个月。
要点
- 维奈克拉联合LDAC较LDAC单药提高CR+CRi率(48% vs 13%)。
核心结论
- 维奈克拉联合LDAC较LDAC单药在缓解率和OS方面显示有临床意义的改善,安全性可控。
- 结果确认维奈克拉联合LDAC是不适合强化化疗的AML患者的重要一线治疗。
研究设计与样本
- 国际3期随机双盲安慰剂对照试验,纳入211例不适合强化化疗的新诊断AML成人患者(年龄≥18岁)。
- 患者按2:1随机接受维奈克拉(n=143)或安慰剂(n=68),联合低剂量阿糖胞苷(LDAC)第1-10天,28天为一周期。
- 主要终点为总生存期(OS);次要终点包括缓解率、输血独立性和无事件生存期。
- 中位年龄76岁(范围36-93岁),38%为继发性AML,20%既往接受过低甲基化药物。
主要发现
- 完全缓解(CR)加血液学计数未完全恢复的完全缓解(CRi)率:维奈克拉联合LDAC组为48%,LDAC单药组为13%。
- 关键≥3级不良事件(维奈克拉 vs LDAC单药):发热性中性粒细胞减少(32% vs 29%)、中性粒细胞减少(47% vs 16%)、血小板减少(45% vs 37%)。
临床怎么用
- 对于不适合强化化疗的新诊断AML成人患者,可考虑维奈克拉联合LDAC作为一线治疗选择。
- 治疗期间需关注≥3级血液学不良事件,如中性粒细胞减少和血小板减少。
局限性
- 额外6个月随访的OS分析为非计划分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. Adults age ≥18 years with newly diagnosed AML ineligible for intensive chemotherapy were enrolled in this international phase 3 randomized double-blind placebo-controlled trial. Patients (N = 211) were randomized 2:1 to venetoclax (n = 143) or placebo (n = 68) in 28-day cycles, plus low-dose cytarabine (LDAC) on days 1 to 10. Primary end point was overall survival (OS); secondary end points included response rate, transfusion independence, and event-free survival. Median age was 76 years (range, 36-93 years), 38% had secondary AML, and 20% had received prior hypomethylating agent treatment. Planned primary analysis showed a 25% reduction in risk of death with venetoclax plus LDAC vs LDAC alone (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.52-1.07; P = .11), although not statistically significant; median OS was 7.2 vs 4.1 months, respectively. Unplanned analysis with additional 6-month follow-up demonstrated median OS of 8.4 months for the venetoclax arm (HR, 0.70; 95% CI, 0.50-0.98; P = .04). Complete remission (CR) plus CR with incomplete blood count recovery rates were 48% and 13% for venetoclax plus LDAC and LDAC alone, respectively. Key grade ≥3 adverse events (venetoclax vs LDAC alone) were febrile neutropenia (32% vs 29%), neutropenia (47% vs 16%), and thrombocytopenia (45% vs 37%). Venetoclax plus LDAC demonstrates clinically meaningful improvement in remission rate and OS vs LDAC alone, with a manageable safety profile. Results confirm venetoclax plus LDAC as an important frontline treatment for AML patients unfit for intensive chemotherapy. This trial was registered at www.clinicaltrials.gov as #NCT03069352.
引用
- Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020. PMID: 32219442. doi:10.1182/blood.2020004856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。